Evaluation of sFlt-1/PlGF Ratio ,OPG and sEng as Predictive Biomarkers in the Diagnosis and Treatment Evaluation of Preeclampsia
Recruiting · NCT07349277 · Observational (researchers observe without assigning treatment) · Lead sponsor: Ammar Jassim Abed
View the official record on ClinicalTrials.gov →What this trial is about
his study investigates the effectiveness of three specific biological markers (biomarkers) in the blood-the sFlt-1/PlGF ratio, soluble endoglin (sEng), and osteoprotegerin (OPG)-to better diagnose and monitor preeclampsia. Preeclampsia is a serious pregnancy complication characterized by high blood pressure and potential organ damage that affects 2-8% of pregnancies worldwide
Who can take part
Age range
18 Years to 45 Years
Sex
Female
Healthy volunteers
Yes - healthy volunteers may be accepted
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Pregnant women between 20 and 36 weeks of gestation
- Age between 18 and 45 years
- Attending the antenatal clinic at the study site
Exclusion criteria
- Chronic hypertension
- Renal disease
- Diabetes mellitus
- Multiple gestations
- Autoimmune disorders
Where it is running
1 location listed.
- Bint Al Huda Maternity Hospital - Nasiriyah, Dhi Qar, Iraq